Ka On Lam

2.9k total citations
40 papers, 501 citations indexed

About

Ka On Lam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ka On Lam has authored 40 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in Ka On Lam's work include Gastric Cancer Management and Outcomes (11 papers), Colorectal Cancer Treatments and Studies (10 papers) and Esophageal Cancer Research and Treatment (8 papers). Ka On Lam is often cited by papers focused on Gastric Cancer Management and Outcomes (11 papers), Colorectal Cancer Treatments and Studies (10 papers) and Esophageal Cancer Research and Treatment (8 papers). Ka On Lam collaborates with scholars based in Hong Kong, China and United Kingdom. Ka On Lam's co-authors include Victor Lee, Queenie Chan, Vincent Lai, Pek Lan Khong, Dora L.�W. Kwong, Wing‐Lok Chan, Cheuk‐Wai Choi, Yhi Wong, Simon Law and Chi‐Leung Chiang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Ka On Lam

37 papers receiving 496 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ka On Lam Hong Kong 13 210 171 157 122 62 40 501
Sang Hoon Chun South Korea 16 237 1.1× 178 1.0× 73 0.5× 51 0.4× 141 2.3× 54 564
Hui Chang China 15 399 1.9× 158 0.9× 125 0.8× 275 2.3× 125 2.0× 47 662
Zhi‐Qing Long China 12 237 1.1× 80 0.5× 37 0.2× 70 0.6× 128 2.1× 30 483
Nariyasu Nakashima Japan 10 339 1.6× 162 0.9× 56 0.4× 73 0.6× 80 1.3× 28 565
Jeanette Ceberg Sweden 9 112 0.5× 127 0.7× 137 0.9× 83 0.7× 59 1.0× 10 354
Xiaobo He China 7 412 2.0× 215 1.3× 22 0.1× 81 0.7× 166 2.7× 8 561
Jacqueline Foidart-Willems Belgium 5 73 0.3× 146 0.9× 252 1.6× 81 0.7× 78 1.3× 8 458
Nalan Akgül Babacan Türkiye 14 307 1.5× 172 1.0× 42 0.3× 84 0.7× 86 1.4× 51 549
Fabio Marazzi Italy 12 156 0.7× 100 0.6× 91 0.6× 59 0.5× 76 1.2× 51 399
Judit Kocsis Hungary 9 164 0.8× 79 0.5× 59 0.4× 45 0.4× 26 0.4× 38 341

Countries citing papers authored by Ka On Lam

Since Specialization
Citations

This map shows the geographic impact of Ka On Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ka On Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ka On Lam more than expected).

Fields of papers citing papers by Ka On Lam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ka On Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ka On Lam. The network helps show where Ka On Lam may publish in the future.

Co-authorship network of co-authors of Ka On Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Ka On Lam. A scholar is included among the top collaborators of Ka On Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ka On Lam. Ka On Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lo, Anthony W.I., Ho Ko, Dora L.�W. Kwong, et al.. (2024). Shift in Tissue-Specific Immune Niches and CD137 Expression in Tuberculoma of Pembrolizumab-Treated Nasopharyngeal Carcinoma Patients. Cancers. 16(2). 268–268.
2.
Kang, Wei, Vincent Ka Chun Yan, Yue Wei, et al.. (2024). Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis. Nature Communications. 15(1). 5657–5657. 3 indexed citations
3.
Kang, Wei, Vincent Ka Chun Yan, Daoud Al‐Badriyeh, et al.. (2024). Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis. Journal of Pharmaceutical Policy and Practice. 17(1). 2375269–2375269.
4.
Ko, Josephine Mun Yee, Ka On Lam, Dora L.�W. Kwong, et al.. (2023). Circulating Tumor Cell Enumeration for Serial Monitoring of Treatment Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancers. 15(3). 832–832. 10 indexed citations
5.
Qiu, Miao‐Zhen, Hongming Pan, Ka On Lam, et al.. (2023). An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.. Journal of Clinical Oncology. 41(4_suppl). 402–402. 5 indexed citations
6.
7.
Lin, Cheng, Shao Hui Huang, Brian O’Sullivan, et al.. (2022). Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. Oral Oncology. 126. 105736–105736. 11 indexed citations
8.
She, Wong Hoi, Tan To Cheung, Simon H. Y. Tsang, et al.. (2022). Long-term survival in colorectal liver metastasis. Langenbeck s Archives of Surgery. 407(8). 3533–3541. 4 indexed citations
9.
Helali, Aya El, Charlene H. L. Wong, Wing‐Lok Chan, et al.. (2022). A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. Frontiers in Oncology. 12. 14 indexed citations
10.
Lam, Tai‐Chung, Cheuk‐Wai Choi, Victor Lee, et al.. (2021). Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. Lung Cancer. 159. 18–26. 53 indexed citations
11.
Ko, Josephine Mun Yee, Ka On Lam, K.W. Chiu, et al.. (2020). Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma. Cancers. 12(6). 1352–1352. 13 indexed citations
12.
Chan, Wing‐Lok, Cheuk‐Wai Choi, Chi‐Leung Chiang, et al.. (2020). Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma. Advances in Radiation Oncology. 5(5). 880–888. 46 indexed citations
13.
14.
Chan, Wing‐Lok, Ka On Lam, Victor Lee, et al.. (2019). Gastric Cancer – From Aetiology to Management: Differences Between the East and the West. Clinical Oncology. 31(8). 570–577. 24 indexed citations
15.
Kwong, Dora L.�W. & Ka On Lam. (2018). Radiotherapy for Esophageal Adenocarcinoma. Methods in molecular biology. 1756. 7–17. 1 indexed citations
16.
Lam, Ka On, Anthony W.I. Lo, Cheuk‐Wai Choi, et al.. (2017). PD-L1 hotspot in tumor-infiltrating lymphocytes of radically treated esophageal squamous cell carcinoma: Pattern of recurrence and long-term clinical outcomes. Annals of Oncology. 28. iii2–iii3. 2 indexed citations
17.
Lai, Vincent, et al.. (2014). Intravoxel water diffusion heterogeneity MR imaging of nasopharyngeal carcinoma using stretched exponential diffusion model. European Radiology. 25(6). 1708–1713. 25 indexed citations
18.
Lai, Vincent, Xiao Li, Victor Lee, et al.. (2013). Intravoxel incoherent motion MR imaging: comparison of diffusion and perfusion characteristics between nasopharyngeal carcinoma and post-chemoradiation fibrosis. European Radiology. 23(10). 2793–2801. 56 indexed citations
19.
Lai, Vincent, Xiao Li, Victor Lee, et al.. (2013). Nasopharyngeal carcinoma: comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging. European Radiology. 24(1). 176–183. 48 indexed citations
20.
Lam, Ka On, et al.. (2012). Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. Oncology Letters. 5(2). 637–640. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sang Hoon Chun Breakdown of academic impact, for papers by Hui Chang Breakdown of academic impact, for papers by Zhi‐Qing Long Breakdown of academic impact, for papers by Nariyasu Nakashima Breakdown of academic impact, for papers by Jeanette Ceberg Breakdown of academic impact, for papers by Xiaobo He Breakdown of academic impact, for papers by Jacqueline Foidart-Willems Breakdown of academic impact, for papers by Nalan Akgül Babacan Breakdown of academic impact, for papers by Fabio Marazzi Breakdown of academic impact, for papers by Judit Kocsis
Rankless by CCL
2026